CeriBell (NASDAQ:CBLL) Stock Price Up 4% - What's Next?

Key Points

• CeriBell shares rose about 4% to roughly $24.59, bringing the company’s market capitalization to approximately $941 million.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $27; TD Cowen recently raised its target to $33.
• The company reported quarterly revenue above expectations but missed on EPS, while negative margins and recent insider selling remain concerns. Institutional investors, including Bank of America and Wellington Management, have recently added or increased positions.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report)'s stock price shot up 4% during trading on Monday. The stock traded as high as $24.43 and last traded at $24.5850. 318,852 shares changed hands during trading, a decline of 7% from the average session volume of 341,821 shares. The stock had previously closed at $23.63.

Wall Street Analysts Forecast Growth

CBLL has been the topic of a number of research analyst reports. TD Cowen boosted their price target on CeriBell from $29.00 to $33.00 and gave the company a "buy" rating in a report on Friday, October 2nd. Weiss Ratings lowered shares of CeriBell from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, October 2nd. Canaccord Genuity Group boosted their target price on shares of CeriBell from $25.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. Barclays upgraded shares of CeriBell to a "neutral" rating in a report on Tuesday, August 18th. Finally, BTIG Research restated a "buy" rating and issued a $30.00 price target on shares of CeriBell in a research note on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $27.00.

CeriBell Stock Up 3.7%

The company's 50-day moving average price is $23.39 and its 200 day moving average price is $20.42. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. The stock has a market cap of $940.89 million, a PE ratio of -13.93 and a beta of 0.94.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Insider Activity at CeriBell

In other CeriBell news, CTO Raymond Woo sold 4,887 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $24.33, for a total value of $118,900.71. Following the completion of the transaction, the chief technology officer directly owned 203,118 shares in the company, valued at $4,941,860.94. This represents a 2.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Scott Blumberg sold 33,512 shares of the firm's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $25.03, for a total value of $838,805.36. Following the transaction, the chief financial officer owned 148,121 shares of the company's stock, valued at approximately $3,707,468.63. The trade was a 18.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 174,905 shares of company stock worth $4,312,995 in the last 90 days. Company insiders own 17.70% of the company's stock.

Institutional Investors Weigh In On CeriBell

Institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC purchased a new stake in CeriBell in the second quarter worth about $638,000. Wellington Management Group LLP increased its position in CeriBell by 5.5% during the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company's stock valued at $1,706,000 after purchasing an additional 4,572 shares during the period. Formula Growth Ltd. bought a new stake in shares of CeriBell in the 2nd quarter valued at about $603,000. Bank of America Corp DE bought a new stake in shares of CeriBell in the 2nd quarter valued at about $4,619,000. Finally, PDT Partners LLC purchased a new stake in shares of CeriBell in the 2nd quarter worth approximately $1,026,000.

About CeriBell

CeriBell, Inc develops medical technology designed to make electroencephalography (EEG) more accessible in acute-care settings. Its primary product is the Ceribell Rapid Response EEG system, a portable, point-of-care platform that enables clinicians to record and assess brain activity at the bedside, including when evaluating patients for seizures and status epilepticus.

The Ceribell system combines a simplified EEG headband and recording device with software that supports rapid interpretation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.